Announced details
Breast and ovarian cancer; patient stratification and treatment strategies in cancer therapy
Confirmed that loss of CDK10 function enhances the antitumor effect of CTX-439
Joint research relationship concerning the identification of sensitivity biomarkers for CTX-439.
Professor Yusa Kosuke (遊佐宏介) of the Institute for Life and Medical Sciences, Kyoto University, is the principal investigator. Other information, including the location, capital, and year established, is not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Cell Death & Disease、Nature Portfolio
| Item | Details |
|---|---|
| Names of Products / Services Covered | CDK12 inhibitor CTX-439, CDK12/13 inhibitor CTX-439 |
| Counterparty | Kyoto University |
| Counterparty overview | Professor Yusa Kosuke (遊佐宏介) of the Institute for Life and Medical Sciences, Kyoto University, is the principal investigator. Other information, including the location, capital, and year established, is not disclosed. |
| Relationship with the Company | Joint research relationship concerning the identification of sensitivity biomarkers for CTX-439. |
| Applicable area | Breast and ovarian cancer; patient stratification and treatment strategies in cancer therapy |
| Quantitative Effects | Confirmed that loss of CDK10 function enhances the antitumor effect of CTX-439 |
| Source | Cell Death & Disease、Nature Portfolio |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Joint research results were obtained on the identification of sensitivity biomarkers based on the mechanism of action of CTX-439.